Birtamimab - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

UK Agri-Tech Centre is losing around 80 roles. What happens to its 43 facilities now?

Representative image of an HDFC Bank building; lender responds to FIR against CEO amid ₹65 crore loan recovery dispute.

Why does Kaizad Bharucha’s exit matter just as HDFC Bank brings in its first external CEO?

Why is Funcom shrinking after Dune: Awakening completed its biggest launch cycle?

Zetwerk Manufacturing Businesses Limited launches its ₹5,012 crore IPO at a price band of ₹143 to ₹151 per share, attracting attention to India's manufacturing growth, industrial supply chains and renewable energy expansion as the company plans to use fresh capital to reduce debt and strengthen its financial position. Representative image.

Zetwerk targets Rs 25,583cr valuation as Rs 5,012cr IPO opens this week

Read More

Pharma Industry News

Prothena halts birtamimab development after Phase 3 AFFIRM-AL trial fails to meet endpoints

Prothena ends birtamimab development after failed Phase 3 trial in AL amyloidosis. Find out how this impacts its pipeline, financials, and future direction.

byPallavi Madhiraju

May 24, 2025

web analytics